ARIZONA HOUSE OF REPRESENTATIVES Fifty-sixth Legislature Second Regular Session
	Senate: FICO DP 4-2-1-0 | APPROP 7-2-1-0 | 3^rd Read 20-7-0-3 House: MAPS DPA 15-0-0-0

---

SB 1677: firefighters; peace officers; PTSD; therapy

Sponsor: Senator Gowan, LD 19

House Engrossed

Overview

Establishes, contingent upon federal approval, coverage for firefighters and certified peace officers (first responders) diagnosed with post-traumatic stress disorder (PTSD), to be treated with midomafetamine, with provisions for implementation in concert with the Industrial Commission of Arizona (ICA).

History

A.R.S. § 36-2517.01 allows any compound, mixture or preparation that contains MDMA (international nonproprietary name: midomafetamine) and is approved by the U.S. Food and Drug Administration (FDA) and rescheduled by the U.S. Drug Enforcement Administration as a Schedule other than a Schedule I controlled substance to be prescribed in Arizona. MDMA is a synthetic chemical that acts as both a stimulant and psychedelic. MDMA is currently a Schedule I controlled substance (DEA Fact Sheet, Ecstasy/MDMA).

If an employee of this state receives an injury by accident arising out of employment, he is entitled to workers' compensation (A.R.S.  23-904). Mental injuries are considered to have arisen out of employment if some unexpected stress related to the employment, or some physical injury related to the employment, was a substantial contributing cause of the mental injury (A.R.S. § 23-1043.01).

Provisions

1. Mandates employers provide workers' compensation coverage for first responders diagnosed with PTSD by a licensed mental health professional. (Sec. 1)

2. Permits the inclusion of midomafetamine in workers' compensation coverage if deemed necessary and reasonable by an independent medical examination and if midomafetamine is integrated into the ICA's treatment guidelines. (Sec. 1)

3. Conditions enactment of this Act upon the FDA approving midomafetamine for PTSD treatment by December 31, 2025. (Sec. 2)

4. Instructs the Arizona Department of Health Services to notify the ICA and Legislative Council by February 2, 2026, of the FDA's decision. (Sec. 2)

5. Directs the ICA to assign reimbursement values in its schedule of fees and publish guidelines on billing and reimbursement practices for midomafetamine upon receiving notification from the Arizona Department of Health Services. (Sec. 3)

6. Requires the ICA to submit an annual report on the costs of midomafetamine treatment to the Joint Legislative Budget Committee by January 1, 2026. (Sec. 1)

7. Defines pertinent terms. (Sec. 1)

8.

9.

10. ---------- DOCUMENT FOOTER ---------

11.                   SB 1677

12. Initials NM          Page 0 House Engrossed

13.

14. ---------- DOCUMENT FOOTER ---------